Literature DB >> 17699134

The importance of diagnosing and managing ICU delirium.

Brenda T Pun1, E Wesley Ely.   

Abstract

ICU delirium represents a form of brain dysfunction that in many cohorts has been diagnosed in 60 to 85% of patients receiving mechanical ventilation. This organ dysfunction is grossly underrecognized because a majority of patients have hypoactive or "quiet" delirium characterized by "negative" symptoms (eg, inattention and a flat affect) not alarming the treating team. Hyperactive delirium, formerly called ICU psychosis, stands out because of symptoms such as agitation that may cause harm to self or staff, but is actually rare relative to hypoactive delirium and associated with a better prognosis. Delirium is often incorrectly thought to be transient and of little consequence. After adjusting for numerous covariates, delirium is a strong, independent predictor of prolonged length of stay, reintubation, higher mortality, and cost of care. Expanded work on patient safety and recommendations by professional societies have established the importance of delirium monitoring and recommended it as standard practice in ICUs all over the world. This evidence-based review for physicians, nurses, respiratory therapists, and pharmacists will outline why it is imperative that patients be routinely monitored for delirium. This review will discuss modifiable risk factors for delirium, such as metabolic disturbances or potent sedative and analgesic medications. Attention to mitigating risk factors, along with recommended pharmacologic approaches such as antipsychotic medications, may provide resolution of delirium in some patients, while others will persist with refractory brain dysfunction and long-term cognitive impairment following critical illness.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17699134     DOI: 10.1378/chest.06-1795

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  50 in total

1.  A Standardized, Structured Approach to Identifying Drug-Related Problems in the Intensive Care Unit: FASTHUG-MAIDENS.

Authors:  Vincent H Mabasa; Douglas L Malyuk; Elisa-Marie Weatherby; Alice Chan
Journal:  Can J Hosp Pharm       Date:  2011-09

Review 2.  Pharmacological and nonpharmacological management of delirium in critically ill patients.

Authors:  Dustin M Hipp; E Wesley Ely
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 3.  [Delirium in the elderly].

Authors:  Manfred Gogol
Journal:  Z Gerontol Geriatr       Date:  2008-10-30       Impact factor: 1.281

Review 4.  Delirium: where do we stand?

Authors:  Chi-Un Pae; David M Marks; Changsu Han; Ashwin A Patkar; Prakash Masand
Journal:  Curr Psychiatry Rep       Date:  2008-06       Impact factor: 5.285

5.  Metabolic Encephalopathy: Behind the Name.

Authors:  Eelco F M Wijdicks
Journal:  Neurocrit Care       Date:  2018-12       Impact factor: 3.210

6.  Evaluation of the prevalence and risk factors of delirium in cardiac surgery ICU.

Authors:  Kamran Shadvar; Farzaneh Baastani; Ata Mahmoodpoor; Eissa Bilehjani
Journal:  J Cardiovasc Thorac Res       Date:  2013-12-05

Review 7.  The ABCDEF Bundle in Critical Care.

Authors:  Annachiara Marra; E Wesley Ely; Pratik P Pandharipande; Mayur B Patel
Journal:  Crit Care Clin       Date:  2017-04       Impact factor: 3.598

8.  Agitation, Delirium, and Cognitive Outcomes in Intracerebral Hemorrhage.

Authors:  Lisa J Rosenthal; Brandon A Francis; Jennifer L Beaumont; David Cella; Michael D Berman; Matthew B Maas; Eric M Liotta; Robert Askew; Andrew M Naidech
Journal:  Psychosomatics       Date:  2016-08-05       Impact factor: 2.386

9.  Off-Label Use of Dexmedetomidine for the Treatment of Delirium in the Intensive Care Unit.

Authors:  Huan Mark Nguyen; Doreen Pon
Journal:  P T       Date:  2016-10

10.  Nicotine withdrawal and agitation in ventilated critically ill patients.

Authors:  Olivier Lucidarme; Amélie Seguin; Cédric Daubin; Michel Ramakers; Nicolas Terzi; Patrice Beck; Pierre Charbonneau; Damien du Cheyron
Journal:  Crit Care       Date:  2010-04-09       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.